Open AccessProspective Evaluation of Genetic Variation in Platelet Endothelial Aggregation Receptor 1 Reveals Aspirin‐Dependent Effects on Platelet Aggregation Pathways
Author(s) -
Backman JD,
YergesArmstrong LM,
Horenstein RB,
Newcomer S,
Shaub S,
Morrisey M,
Donnelly P,
Drolet M,
Tanner K,
Pavlovich MA,
O'Connell JR,
Mitchell BD,
Lewis JP
Publication year - 2017
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12438
Subject(s) - aspirin , platelet , adenosine diphosphate , agonist , platelet aggregation , epinephrine , pharmacology , medicine , platelet aggregation inhibitor , platelet activation , receptor
Genetic variation in the platelet endothelial aggregation receptor 1 ( PEAR1 ) gene, most notably rs12041331, is implicated in altered on‐aspirin platelet aggregation and increased cardiovascular event risk. We prospectively tested the effects of aspirin administration at commonly prescribed doses (81, 162, and 324 mg/day) on agonist‐induced platelet aggregation by rs12041331 genotype in 67 healthy individuals. Prior to aspirin administration, rs12041331 minor allele carriers had significantly reduced adenosine diphosphate (ADP)‐induced platelet aggregation compared with noncarriers ( P = 0.03) but was not associated with other platelet pathways. In contrast, rs12041331 was significantly associated with on‐aspirin platelet aggregation when collagen and epinephrine were used to stimulate platelet aggregation ( P < 0.05 for all associations), but not ADP. The influence of PEAR1 rs12041331 on platelet aggregation is pathway‐specific and is altered by aspirin at therapeutic doses, but not in a dose‐dependent manner. Additional studies are needed to determine the impact of PEAR1 on cardiovascular events in aspirin‐treated patients.